Introduction
Artificial intelligence is becoming increasingly relevant across the Life Sciences industry.
Its applications extend beyond drug discovery. AI is being explored across areas including research, clinical development, manufacturing, quality, regulatory activities and data analysis.
The FDA reports increasing use of AI across the drug product lifecycle, including nonclinical, clinical, postmarketing and manufacturing activities.
This creates an opportunity to connect scientific data, operational workflows and regulatory information through more intelligent digital systems.
What Is AI in Life Sciences?
AI in Life Sciences refers to the application of artificial intelligence and machine learning technologies to scientific, healthcare, pharmaceutical and biotechnology workflows.
Potential applications include:
- Scientific data analysis
- Drug development
- Clinical operations
- Manufacturing
- Quality management
- Regulatory processes
- Knowledge management
- Predictive analytics
- Decision support
AI in Pharmaceutical Development
AI can support different stages of the pharmaceutical development lifecycle.
Potential areas include:
Research — analysing complex scientific datasets.
Development — supporting data-driven formulation and development activities.
Clinical — helping analyse clinical and operational data.
Manufacturing — supporting process and quality analytics.
Post-market — analysing relevant safety and product information.
FDA notes that AI components have appeared in drug submissions across multiple stages of the product lifecycle.
AI in Regulatory & Quality
Regulatory and quality operations generate large volumes of structured and unstructured information.
AI can potentially support:
- Document analysis
- Information extraction
- Regulatory intelligence
- Quality data analysis
- Knowledge retrieval
- Workflow automation
- Decision support
However, AI used in regulated environments requires appropriate controls around context of use, data governance, documentation, performance and lifecycle management. FDA/EMA guiding principles for AI in drug development specifically emphasize these areas.
AI in Biotechnology & Research
Biotechnology and scientific research generate increasingly complex datasets.
AI can help organizations explore relationships across scientific information, identify patterns and support data-driven research workflows.
From AI Tools to Life Sciences Intelligence
The next stage is not simply adding AI to individual applications.
The greater opportunity is connecting intelligence across:
Regulatory → Quality → Clinical → Manufacturing → Scientific Workflows
This creates a more unified view of information across the Life Sciences lifecycle.
Garvimi by SIX8
Garvimi is SIX8’s Life & Bio Sciences Intelligence platform.
Garvimi empowers pharma, biotech, and research organizations with unified intelligence across regulatory, quality, clinical, manufacturing, and scientific workflows.
The broader vision is to connect these domains through a unified intelligence environment rather than treating each workflow as an isolated system.
The Future of AI in Life Sciences
AI will continue to evolve across Life Sciences, but meaningful adoption depends on more than algorithms.
Organizations also need:
- High-quality data
- Appropriate governance
- Clear use cases
- Domain expertise
- Validated workflows
- Human oversight
- Regulatory awareness
The future of Life Sciences intelligence will therefore depend on bringing scientific expertise, technology, data and governance together.